This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New "Epocrates Bugs + Drugs" App Harnesses Big Data For Better, Personalized Patient Care

SANTA CLARA, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) -- According to a report recently issued by the Centers for Disease Control and Prevention (CDC), every year more than two million people in the U.S. contract infections that are resistant to antibiotics and at least 23,000 people die as a result. Antibiotic resistant bacteria or "superbugs" such as resistant E. coli and staph are of great concern because they are increasingly impervious to typical antibiotics. To compound the problem, many clinicians who work outside of hospitals are unaware of the bacteria types pervasive in their local areas. Today, from the 7th Annual Health 2.0 Conference in Santa Clara, California, athenahealth, Inc. (Nasdaq:ATHN) and Epocrates together announced a new, free mobile app, "Epocrates Bugs + Drugs," to arm clinicians with timely geolocated information about bacteria types and resistance patterns, and to support appropriate antibiotic prescribing.

"Epocrates Bugs + Drugs is a game-changer in the clinical toolbox. Traditionally, hospitals have tracked resistance trends on inpatients. Now, Bugs + Drugs goes beyond the hospital setting, transforming lab results from athenahealth's cloud-based EHR database of 15 million patients into geotargeted data to help physicians identify common and uncommon bugs in the communities where their patients live. Clinicians can access critical resistance information to formulate the best treatment plan.  It's one step closer to personalized medicine," said Dr. Anne Meneghetti, Executive Director of Medical Information at Epocrates, an athenahealth company. "This app is a perfect example of pairing athenahealth's big data with Epocrates' mobile expertise to better equip caregivers to make confident and efficient decisions in the moments of care. Decisions made in those moments can affect future antibiotic resistance for the entire population." 

"The convenience of this app with its localized content provides great insights from an infectious diseases perspective. The real-time, geographic-specific information of the proportions of specific organisms for a particular type of infection and the susceptibility profiles of those organisms allows for more prudent use of antibiotics, which is a major benefit to the patient and the health system," said Dr. Rajesh Gupta, Infectious Disease Specialist.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs